Have a personal or library account? Click to login
Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells Cover

Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells

Radiology and Oncology
Volume 56 (2022): Issue 2 (June 2022)
By:
Open Access
|Mar 2022

Figures & Tables

Figure 1

Survival fraction of BxPC-3 cells after electrochemotherapy (ECT). Survival of cells treated with ECT with bleomycin after 3 days (A) and 7 days (B) and survival fraction of BxPC-3 cells treated with ECT with cisplatin after 3 (C) and 7 days (D). The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3.
Survival fraction of BxPC-3 cells after electrochemotherapy (ECT). Survival of cells treated with ECT with bleomycin after 3 days (A) and 7 days (B) and survival fraction of BxPC-3 cells treated with ECT with cisplatin after 3 (C) and 7 days (D). The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3.

Figure 2

Targeted therapy of BxPC-3 pancreatic carcinoma cells with sunitinib. (A) Expression of different tyrosine kinases as sunitinib targets; n = 2. Surviving fraction of BxPC-3 cells treated with different sunitinib concentrations incubated for (B) 3 and (C) 7 days. The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3. FLT1 = fms related receptor tyrosine kinase 1/VEGFR1; FLT3 = fms related receptor tyrosine kinase 3; KDR = kinase insert domain receptor/VEGFR2; KIT = KIT proto-oncogene; RET = ret proto-oncogene; PDGFR = platelet-derived growth factor receptor
Targeted therapy of BxPC-3 pancreatic carcinoma cells with sunitinib. (A) Expression of different tyrosine kinases as sunitinib targets; n = 2. Surviving fraction of BxPC-3 cells treated with different sunitinib concentrations incubated for (B) 3 and (C) 7 days. The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3. FLT1 = fms related receptor tyrosine kinase 1/VEGFR1; FLT3 = fms related receptor tyrosine kinase 3; KDR = kinase insert domain receptor/VEGFR2; KIT = KIT proto-oncogene; RET = ret proto-oncogene; PDGFR = platelet-derived growth factor receptor

Figure 3

Surviving fraction of BxPC-3 cells treated with ECT monotherapy with bleomycin (A) or cisplatin (B) combined with 2.5, 5 or 7.5 μM sunitinib. The values are presented as the AM ± SEM. *p < 0.05 statistically significant difference vs. annotated groups, n = 3.
Surviving fraction of BxPC-3 cells treated with ECT monotherapy with bleomycin (A) or cisplatin (B) combined with 2.5, 5 or 7.5 μM sunitinib. The values are presented as the AM ± SEM. *p < 0.05 statistically significant difference vs. annotated groups, n = 3.

Figure 4

The combination of ECT with bleomycin and sunitinib resulted in a higher number of dead cells. (A) Number of dead cells detected every 4 hours during kinetic measurement (A) after ECT single treatment, (B) after addition of 2.5, 5 or 7.5 μM sunitinib to Ctrl, (C) after addition of 2.5, 5 or 7.5 μM sunitinib to EP and (D) after addition of 2.5, 5 or 7.5 μM sunitinib to ECT. The values are presented as the AM ± SEM. *p < 0.05 vs. annotated groups, n = 3. Ctrl = untreated control cells; ECT = electrochemotherapy; EP = electroporated cells only
The combination of ECT with bleomycin and sunitinib resulted in a higher number of dead cells. (A) Number of dead cells detected every 4 hours during kinetic measurement (A) after ECT single treatment, (B) after addition of 2.5, 5 or 7.5 μM sunitinib to Ctrl, (C) after addition of 2.5, 5 or 7.5 μM sunitinib to EP and (D) after addition of 2.5, 5 or 7.5 μM sunitinib to ECT. The values are presented as the AM ± SEM. *p < 0.05 vs. annotated groups, n = 3. Ctrl = untreated control cells; ECT = electrochemotherapy; EP = electroporated cells only
DOI: https://doi.org/10.2478/raon-2022-0009 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 164 - 172
Submitted on: Feb 10, 2022
Accepted on: Mar 2, 2022
Published on: Mar 28, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
electrochemotherapy,
ECT,
pancreas,
sunitinib,
bleomycin,
tyrosine-kinase inhibitors,
pancreatic cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2022 Masa Bosnjak, Tanja Jesenko, Bostjan Markelc, Anja Cerovsek, Gregor Sersa, Maja Cemazar, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 56 (2022): Issue 2 (June 2022)Next article